

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

### SECTION 1. IDENTIFICATION

Product name : Doravirine Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

#### GHS label elements

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	$\geq 20 - < 30$
Doravirine	1338225-97-0	$\geq 10 - < 20$
Magnesium stearate	557-04-0	$\geq 1 - < 5$
Silicon, amorphous	112945-52-5	$\geq 1 - < 5$

Actual concentration is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

- If inhaled : advice.  
: If inhaled, remove to fresh air.  
: Get medical attention if symptoms occur.
  - In case of skin contact : Wash with water and soap.  
: Get medical attention if symptoms occur.
  - In case of eye contact : If in eyes, rinse well with water.  
: Get medical attention if irritation develops and persists.
  - If swallowed : If swallowed, DO NOT induce vomiting.  
: Get medical attention if symptoms occur.  
: Rinse mouth thoroughly with water.
  - Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
: Dust contact with the eyes can lead to mechanical irritation.
  - Protection of first-aiders : No special precautions are necessary for first aid responders.
  - Notes to physician : Treat symptomatically and supportively.
- 

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
: Alcohol-resistant foam  
: Carbon dioxide (CO<sub>2</sub>)  
: Dry chemical
  - Unsuitable extinguishing media : None known.
  - Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
: Exposure to combustion products may be a hazard to health.
  - Hazardous combustion products : Carbon oxides  
: Nitrogen oxides (NO<sub>x</sub>)  
: Halogenated compounds  
: Metal oxides
  - Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
: Use water spray to cool unopened containers.  
: Remove undamaged containers from fire area if it is safe to do so.  
: Evacuate area.
  - Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.  
: Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
: Prevent further leakage or spillage if safe to do so.  
: Retain and dispose of contaminated wash water.  
: Local authorities should be advised if significant spillages

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

---

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m <sup>3</sup> Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m <sup>3</sup>

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

15 Million particles per cubic foot  
Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

Dust, nuisance dust and particulates

10 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (Total dust)  
Basis: CAL PEL

5 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (respirable dust fraction)  
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1
Doravirine	1338225-97-0	TWA	500 ug/m <sup>3</sup> (OEB2)	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Silicon, amorphous	112945-52-5	TWA (Dust)	20 Million particles per cubic foot (Silica)	OSHA Z-3
		TWA (Dust)	80 mg/m <sup>3</sup> / %SiO <sub>2</sub> (Silica)	OSHA Z-3
		TWA	6 mg/m <sup>3</sup> (Silica)	NIOSH REL

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection  
Material

: Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection  
Hygiene measures

: Work uniform or laboratory coat.  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

products

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### Doravirine:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg  
Remarks: No mortality observed at this dose.

(Rat): Method: Phototoxicity  
Remarks: No evidence of phototoxicity was observed

LD50 (Dog): > 1,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 450 mg/kg  
Remarks: No mortality observed at this dose.

##### Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

##### Silicon, amorphous:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg  
Remarks: Based on data from similar materials

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### **Doravirine:**

Remarks : No data available

##### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

##### **Silicon, amorphous:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Doravirine:**

Remarks : No data available

##### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

##### **Silicon, amorphous:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

#### Components:

##### Doravirine:

Remarks : No data available

##### Magnesium stearate:

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

##### Doravirine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative  
Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### Silicon, amorphous:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### Doravirine:

Species : Mouse  
Application Route : Oral  
Exposure time : 6 Months  
Result : negative  
Remarks : No significant adverse effects were reported

#### Silicon, amorphous:

Species : Rat  
Application Route : Ingestion  
Exposure time : 103 weeks  
Result : negative  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

##### **Doravirine:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male and female  
Fertility: NOAEL: 450 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 450 mg/kg body weight  
Result: No adverse effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 300 mg/kg body weight  
Result: No adverse effects.

##### **Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **Silicon, amorphous:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **STOT-single exposure**

Not classified based on available information.

### **STOT-repeated exposure**

Not classified based on available information.

### **Repeated dose toxicity**

#### **Components:**

##### **Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

##### **Doravirine:**

Species : Rat  
NOAEL : 450 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL :  $> 450$  mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL :  $> 1,000$  mg/kg  
Application Route : Oral  
Exposure time : 9 Months  
Remarks : No significant adverse effects were reported

##### **Magnesium stearate:**

Species : Rat  
NOAEL :  $> 100$  mg/kg

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Silicon, amorphous:**

Species : Rat  
NOAEL : 1.3 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 13 Weeks  
Remarks : Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

#### **Doravirine:**

Ingestion : Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

---

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

#### **Components:**

#### **Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

#### **Doravirine:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 39 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): 9.1 mg/l  
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l  
Exposure time: 72 h

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 6.7 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version 13.0      Revision Date: 07/06/2024      SDS Number: 58388-00027      Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

---

Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### **Silicon, amorphous:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
Exposure time: 24 h  
Method: OECD Test Guideline 202  
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

### **Persistence and degradability**

#### **Components:**

##### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

##### **Doravirine:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 2 %  
Exposure time: 28 d

##### **Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### **Bioaccumulative potential**

#### **Components:**

##### **Doravirine:**

Partition coefficient: n-octanol/water : log Pow: 2.08

##### **Magnesium stearate:**

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

#### Components:

#### Doravirine:

Distribution among environmental compartments : log Koc: 2.86

#### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

Not regulated as a dangerous good

#### Special precautions for user

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

---



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Combustible dust

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate	71138-97-1
Cellulose	9004-34-6
D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5
Doravirine	1338225-97-0
Croscarmellose sodium	74811-65-7

#### California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0
Silicon, amorphous	112945-52-5

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

## SECTION 16. OTHER INFORMATION

### Further information

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation


Version  
13.0

Revision Date:  
07/06/2024

SDS Number:  
58388-00027

Date of last issue: 04/06/2024  
Date of first issue: 02/16/2015

### NFPA 704:



### HMIS® IV:

HEALTH	/	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	:	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
13.0	07/06/2024	58388-00027	Date of first issue: 02/16/2015

---

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 07/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8